Infineon Raises 2026 Outlook as AI Data Center Chip Demand Surges 
Philips Reaffirms 2026 Outlook After Strong Q1 Sales and Margin Beat 
BMW Keeps 2026 Outlook Despite 25% Profit Drop Amid Tariff Pressure 
Strategy Hints at Bitcoin Sales to Cover Dividends After Massive Q1 Loss 
China Banks Halt New Loans to Sanctioned Refineries Amid U.S.-Iran Oil Crackdown 
UOB Q1 Profit Meets Expectations as Loan Growth Offsets Lower Interest Rates 
Apple Explores Intel and Samsung Partnerships to Diversify Chip Supply Chain 
Palantir Reports Record Growth, Raises 2026 Revenue Outlook Above Expectations 
Supermicro Forecasts Strong Q4 Revenue Growth as AI Server Demand Surges 
Pinterest Stock Surges After Strong Q1 2026 Earnings Beat Expectations 
JD Sports Backs Nike CEO Elliott Hill Amid Brand Turnaround Efforts 
Intel Emerges as Key Contender in Apple’s Chip Manufacturing Strategy Shift 
Hua Hong Semiconductor Stock Surges to Multi-Year High Amid AI Boom 
Shell Q1 Profit Surges to Two-Year High as Dividend Rises Despite War-Driven Debt Pressure 
Lufthansa Q1 Loss Narrows as Strong Summer Travel Demand Boosts Outlook 
Continental AG Shares Jump After Q1 Profit Beats Expectations 
Orsted Q1 EBITDA Beats Expectations Despite U.S. Impairments 
(4) - EconoTimes)
CAMBRIDGE, Mass., April 30, 2018 -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a commercial-stage biopharmaceutical company focused on the discovery and development of precision genetic medicine to treat rare neuromuscular diseases, granted equity awards on April 30, 2018, that were previously approved by the Compensation Committee of its Board of Directors under Sarepta’s 2014 Employment Commencement Incentive Plan, as a material inducement to employment to forty individuals hired by Sarepta in April 2018. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4).
The employees received, in the aggregate, options to purchase 170,959 shares of Sarepta's common stock. The options have an exercise price of $76.36 per share, which is equal to the closing price of Sarepta's common stock on April 30, 2018. One-fourth of the shares underlying each employee’s option will vest on the one year anniversary of his or her date of hire and thereafter 1/48th of the shares underlying each employee’s option will vest monthly, such that the shares underlying the option granted to each employee will be fully vested on the fourth anniversary of his or her date of hire, in each case, subject to each such employee’s continued employment with Sarepta on such vesting dates.
About Sarepta Therapeutics
Sarepta Therapeutics is a commercial-stage biopharmaceutical company focused on the discovery and development of precision genetic medicine to treat rare neuromuscular diseases. The Company is primarily focused on rapidly advancing the development of its potentially disease-modifying Duchenne muscular dystrophy (DMD) drug candidates. For more information, please visit www.sarepta.com.
Internet Posting of Information
We routinely post information that may be important to investors in the 'For Investors' section of our website at www.sarepta.com. We encourage investors and potential investors to consult our website regularly for important information about us.
Source: Sarepta Therapeutics, Inc.
Media and Investors:
Sarepta Therapeutics, Inc.
Ian Estepan, 617-274-4052
[email protected]
or
W2O Group
Brian Reid, 212-257-6725
[email protected]
